Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Kyle LaHucik

Senior Reporter

Kyverna Therapeutics has reshaped its C-suite just seven months after securing one of the splashiest biotech IPOs in recent years as it rode the waves …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Conducting trials via routine clinical practice: FDA explains how in new draft guidance

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Breaking down silos with a new quantitative approach to drug development

Ex-Kite lead­ers step in at Kyver­na as CEO ex­its af­ter land­ing year's sec­ond-biggest IPO

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

FDA can­cels Ap­plied Ther­a­peu­tics ad­comm, shares sky­rock­et 65%

All of 23and­Me's in­de­pen­dent board mem­bers re­sign over dis­agree­ments with CEO

Con­duct­ing tri­als via rou­tine clin­i­cal prac­tice: FDA ex­plains how in new draft guid­ance

You bet your life: Af­ter I was di­ag­nosed with a rare can­cer, I dis­cov­ered how a small band of physi­cian-sci­en­tists ...

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

All of 23andMe's independent board members resign over disagreements with CEO

Conducting trials via routine clinical practice: FDA explains how in new draft guidance

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Breaking down silos with a new quantitative approach to drug development